BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
Metrics: PDF 974 views | HTML 1793 views | ?
Mingxing Wang1,*, Wanjun Li2,*, Xuemei Xing3,*, Dan Zhang4, Jie Lei1 and Guoyin Li2,5
1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, China
2Department of Pathology, Hanzhong 3201 Hospital Affiliated to Xi’anJiaotong University, Xi’an, Shaanxi, China
3Department of Clinical Laboratory, Hanzhong 3201 Hospital Affiliated to Xi’anJiaotong University, Xi’an, Shaanxi, China
4Department of Oncology, Hanzhong 3201 Hospital Affiliated to Xi’anJiaotong University, Xi’an, Shaanxi, China
5Department of Biochemistry and Molecular Biology, The Fourth Military Medical University, Xi’an, Shaanxi, China
*These authors are co-first authors
Jie Lei, email: email@example.com
Guoyin Li, email: firstname.lastname@example.org
Keywords: NSCLC, BRCA1 and STMN, chemotherapy, prognosis
Received: April 03, 2017 Accepted: August 08, 2017 Published: September 08, 2017
Objective: In this study, we aimed to investigate the predictive effect of BRCA1, STMN1, MAPT and TUBB3 on the prognosis of patients with non-small cell lung cancer (NSCLC).
Methods: Seventy NSCLC patients who received platinum-based chemotherapy from June 2009 to July 2011 were enrolled. The protein and mRNA levels of BRCA1, STMN1, MAPT and TUBB3 were determined. Survival time of the patients with NSCLC was also calculated.
Results: High expression of BRCA1 or low expression of STMN1 was associated with a better prognosis in NSCLC patients (p<0.01). In contrast, the expression of MAPT and TUBB3 were not closely related with the prognosis of NSCLC patients(p>0.05). Furthermore, patients with high expression of BRCA1 and low expression of STMN1 have lived longer (p<0.01).
Conclusion: BRCA1 and STMN1 were independently predictors for prognosis of NSCLCs which received cisplatin-based adjuvant chemotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.